The study by researchers at the University of Miami Miller School of Medicine, published in the journal EMBO Molecular Medicine, examined the effects of the drug in 29 men diagnosed with prostate cancer. It opens the door to further research into the drug's potential, particularly for cancer patients who often experience fatigue that limits their ability to train. 'These findings suggest Lac-Phe may be a very informative signal for understanding how metformin affects metabolism in prostate cancer patients.' Earlier studies have linked metformin to a lower risk of oesophageal cancer – and suggest the drug could also help guard against prostate cancer. It has been gaining attention as a possible cancer-fighting drug, with research suggesting it can slow the growth of cancer cells.

Source: Daily Mail April 07, 2026 18:02 UTC